Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK

Asan Medical Center17 enrolled

Overview

In patients who are receiving nilotinib, nilotinib plasma levels will be measured after 1 month of nilotinib treatment. The relationship between surgery type and nilotinib pharmakokinetic properties will be investigated in this study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Gastrointestinal Stromal Tumors

Interventions

NilotinibDRUG

Nilotinib 400mg bid daily

Eligibility

Sex: ALLMin age: 15 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with metastatic or unresectable gastrointestinal stromal tumor * Patients receiving nilotinib after failure to imatinib and sunitinib

Locations (1)

Asan Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

nilotinib pharmacokinetics

Time frame: Up to 3years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.